NGM
NGM Biopharmaceuticals, Inc. Common Stock
NGM
NGM
Delisted
NGM was delisted on the 4th of April, 2024.
108 hedge funds and large institutions have $1.25B invested in NGM Biopharmaceuticals, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 39 increasing their positions, 18 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
11% more capital invested
Capital invested by funds: $1.12B → $1.25B (+$127M)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
Holders
108
Holding in Top 10
7
Calls
$1.4M
Puts
$430K
Top Buyers
| 1 | +$80M | |
| 2 | +$14.1M | |
| 3 | +$12M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$11M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$10.9M |
Top Sellers
| 1 | -$17.2M | |
| 2 | -$1.42M | |
| 3 | -$1.42M | |
| 4 |
Invesco
Atlanta,
Georgia
|
-$1.23M |
| 5 |
MS
Maven Securities
St Helier,
Jersey
|
-$1.04M |